🟢 Amneal Pharmaceuticals is trading 6.32% up in pre-market with no clear company-specific catalyst

Amneal Pharmaceuticals is trading 6.32% up now at $19.00 in pre-market on September 4, 2026; no fresh company-specific announcement clearly explains the gain.

• Search results mainly surfaced older developments, including the August 10 Kashiv BioSciences acquisition and July second-quarter earnings.
• A Reuters company page resurfaced the stale May 2025 Brekiya FDA approval, not today’s catalyst.
• Broader market conditions were mixed before payrolls, offering no definitive explanation.